# Study of Gene Modified Immune Cells in Patients With Advanced Melanoma

> **NCT00910650** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells
- **DRUG:** non-myeloablative conditioning chemotherapy

## Key facts

- **NCT ID:** NCT00910650
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-13
- **Primary completion:** 2019-05-30
- **Final completion:** 2019-05-30
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-12-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00910650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00910650, "Study of Gene Modified Immune Cells in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00910650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*